失眠症
医学
中止
恶化
精神科
干预(咨询)
原发性失眠
认知行为疗法
认知
睡眠障碍
内科学
作者
Michael L. Perlis,Donn Posner,Dieter Riemann,Célyne Bastien,Joseph Teel,Michael Thase
出处
期刊:The Lancet
[Elsevier]
日期:2022-09-01
卷期号:400 (10357): 1047-1060
被引量:144
标识
DOI:10.1016/s0140-6736(22)00879-0
摘要
Insomnia is highly prevalent in clinical practice, occurring in up to 50% of primary care patients. Insomnia can present independently or alongside other medical conditions or mental health disorders and is a risk factor for the development and exacerbation of these other disorders if not treated. In 2016, the American College of Physicians recommended that insomnia be specifically targeted for treatment. The recommended first-line treatment for insomnia, whether the underlying cause has been identified or not, is cognitive behavioural therapy for insomnia (CBT-I). Currently, there is no global consensus regarding which pharmacological treatment has the best efficacy or risk-benefit ratio. Both CBT-I and pharmacological intervention are thought to have similar acute effects, but only CBT-I has shown durable long-term effects after treatment discontinuation. Administering a combined treatment of CBT-I and medication could decrease the latency to treatment response, but might diminish the durability of the positive treatment effects of CBT-I. Insomnia is highly prevalent in clinical practice, occurring in up to 50% of primary care patients. Insomnia can present independently or alongside other medical conditions or mental health disorders and is a risk factor for the development and exacerbation of these other disorders if not treated. In 2016, the American College of Physicians recommended that insomnia be specifically targeted for treatment. The recommended first-line treatment for insomnia, whether the underlying cause has been identified or not, is cognitive behavioural therapy for insomnia (CBT-I). Currently, there is no global consensus regarding which pharmacological treatment has the best efficacy or risk-benefit ratio. Both CBT-I and pharmacological intervention are thought to have similar acute effects, but only CBT-I has shown durable long-term effects after treatment discontinuation. Administering a combined treatment of CBT-I and medication could decrease the latency to treatment response, but might diminish the durability of the positive treatment effects of CBT-I. Waking up to the importance of sleepFor decades, sleep and its associated disorders have been considered a Cinderella branch of medicine. The subject receives little attention in undergraduate education, training is an adjunct to other more established specialties, and funding for sleep research is woefully deficient. The reasons for such neglect are embedded in the disparate nature of the conditions grouped together under the heading of sleep disorders—ranging from sleep apnoea, dealt with by an ear, nose, and throat specialist or cardiologist, to restless legs syndrome, handled by a neurologist or primary care physician—as well as a lack of understanding of their causes and the sparsity of treatment options. Full-Text PDF This article can be found in the following collections:Psychiatry
科研通智能强力驱动
Strongly Powered by AbleSci AI